Association between multiple myeloma and acute myeloid leukemia secondary to myelodysplastic syndrome

Jennane, Selim; Eddou, Hicham; Mahtat, El Mehdi; Konopacki, Johanna; Souleau, B.; Malfuson, Jean Valère; Foissaud, Vincent; Revel, Thierry de

doi:10.1684/abc.2013.0880

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some reviewers postulated that secondary AML occurs during complete remission of MM after chemotherapy, other scholars hypothesized that myeloma cells can stimulate bone marrow during cell proliferation, this phenomenon may result in subsequent development of a second hematological malignancy, particularly in cases with Rb-1 deletion [ 5 ]. Reports showed that the underlying monoclonal gammopathy of undetermined significance (MGUS) progresses to MM, resulting in the co-existence of MGUS and AML, particularly in elderly patients [ 9 ]. The simultaneous development of AML and MM in a patient without previous exposure to chemotherapy is a rare event.…”

Section: Discussionmentioning

confidence: 99%

A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma

Wang

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

BackgroundAlthough the occurrence of acute myeloid leukemia (AML) after chemotherapy for multiple myeloma (MM) is common in clinical settings, the simultaneous occurrence of these malignancies in patients without previous exposure to chemotherapy is a rare event. Etiology, disease management, and clinical treatment remain unclear for this particular occurrence. To the best of our knowledge, this study is the first to report a case of simultaneous presentation of AML and MM after exposure to ultraviolet irradiation.Case presentationWe reported the case of a 73-year-old man (Han Chinese ethnicity) without previous medical history of AML and MM. The morphology and immunology of bone marrow cells confirmed the co-existence of AML and MM. Fluorescent in situ hybridization analysis of immunomagnetically separated abnormal plasma cells showed abnormal expression of the amplified RB-1, TP53, and CDKN2C (1p32). Cytogenetic analysis demonstrated Y chromosome deletion.After the patient was administered with bortezomib combined with cytarabine + aclarubicin + granulocyte colony-stimulating factor (CAG regimen), and evident curative effects were observed. The patient achieved and maintained complete remission for more than 6 months. Prior to the disease occurrence, the patient had received ultraviolet irradiation for 1 year and was detected with aberrant gene expression of RB-1, TP53, and CDKN2C (1p32). Nevertheless, the correlation of this phenomenon with the etiology of concurrent AML with MM remains unclear.ConclusionThis study discussed the case of a patient diagnosed with AML concurrent with MM, who has no previous exposure to chemotherapy. This patient was successfully treated by bortezomib combined with CAG regimen. This study provides a basis for clinical treatment guidance for this specific group of patients and for confirmation of the disease etiology.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1743-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma

Wang

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Invasive pulmonary aspergillosis was previously diagnosed as probable in four cases and possible in three others. The median duration of neutropenia before CDC diagnosis was 18 [14][15][16][17][18][19][20][21][22][23][24] days. The median time between CDC diagnosis by imaging and the previous period of neutropenia was 34 [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41] days.…”

Section: Population Characteristicsmentioning

confidence: 99%

“…are able to metabolize F18-fluorodeoxyglucose (12)(13)(14)(15). Indeed, a preliminary study by our team has assessed PET/CT as a diagnostic tool for invasive fungal diseases (IFD), including CDC (16), its appropriateness being further documented by descriptive case reports or small case series uptake (17)(18)(19)(20)(21). PET/CT might therefore help to assess lesions at baseline and monitor antifungal treatment duration of CDC (9,10).…”

Section: Introductionmentioning

confidence: 99%

Does 18F-FDG PET/CT add value to conventional imaging in clinical assessment of chronic disseminated candidiasis?

et al. 2022

View full text Add to dashboard Cite

BackgroundChronic disseminated candidiasis (CDC) classically occurs after profound and prolonged neutropenia. The aim of the CANHPARI study was to assess the clinical value of adding 18F-fluorodeoxyglucose PET/CT to conventional radiology for initial and subsequent evaluations of CDC.Materials and methodsA pilot prospective study was conducted in 23 French onco-hematological centers from 2013 to 2017 (NCT01916057). Patients ≥ 18 y.o. suspected for CDC on abdominal conventional imaging (CT or MRI) were included. PET/CT and conventional imaging were performed at baseline and month 3 (M3). Follow-up was assessed until M12. The primary outcome measure was the global response at M3, i.e., apyrexia and complete response to PET/CT. The secondary outcome measure consists in comparison between responses to PET/CT and conventional imaging at diagnosis and M3.ResultsAmong 52 included patients, 44 were evaluable (20 probable and 24 possible CDC); 86% had acute leukemia, 55% were male (median age 47 years). At diagnosis, 34% had fever and conventional imaging was always abnormal with microabscesses on liver and spleen in 66%, liver in 25%, spleen in 9%. Baseline PET/CT showed metabolic uptake on liver and/or spleen in 84% but did not match with lesion localizations on conventional imaging in 32%. M3 PET/CT showed no metabolic uptake in 13 (34%) patients, 11 still having pathological conventional imaging. Global response at M3 was observed in eight patients.ConclusionBaseline PET/CT does not replace conventional imaging for initial staging of CDC lesions but should be performed after 3 months of antifungal therapy.Clinical trial registration[www.clinicaltrials.gov], identifier [NCT01916057].

show abstract

Association between multiple myeloma and acute myeloid leukemia secondary to myelodysplastic syndrome

Cited by 2 publications

References 0 publications

A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma

A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma

Does 18F-FDG PET/CT add value to conventional imaging in clinical assessment of chronic disseminated candidiasis?

Contact Info

Product

Resources

About